LifeCycle Pharma A/S to Host Conference Call Announcing Result for the first quarter 2011


Investor Service Announcement no.2/2011                                                                                                                                                               

 

To: NASDAQ OMX Copenhagen                                                                             Hørsholm, Denmark, May 4, 2011

 

 

 LifeCycle Pharma A/S to Host Conference Call Announcing

Result for the first quarter 2011

 

LifeCycle Pharma A/S (OMX: LCP) will announce the result for the first quarter 2011 on Tuesday May 10, 2011 after 5 PM. LCP’s Management will host a conference call on May 11, 2011, at 3:00 PM CET (Denmark); 2:00 PM GMT (London), 9:00 AM ET (New York), 6:00 AM PT (San Francisco) to discuss the financial results.

 

To access the live conference call, please dial one of the following numbers:

+45 32 72 76 25 Denmark

+44 (0) 1452 555 566 UK

+1 631 510 7498 USA

Access code 64356225

 

Following the conference call, an audio cast will be available on the company’s website www.lcpharma.com until June 10, 2011. A presentation will be available on LCP’s website (under ‘Investors’) one hour prior to the scheduled time of the conference call.

 

For more information, please contact:

 

 

LifeCycle Pharma A/S  
John Weinberg, M.D.
SVP, Commercial Operations & Investor Relations
Phone: +1 732 321 3208
Email: jdw@lcpharma.com
 
 
Johnny Stilou
CFO
Phone: + 45 2055 3817
Email: jst@lcpharma.com
 

                                                                                                                                                                                                               

About LifeCycle Pharma A/S (LCP)

Based in Hørsholm, Denmark, with an office in New Jersey, LCP is a specialty pharmaceutical company. Clinical development is the core of LCP's efforts to develop a product portfolio which includes the Company’s lead product candidate, LCP‐Tacro™, for immunosuppression, specifically organ transplantation, and products to combat certain cardiovascular diseases. LCP adapts new technologies on a fast commercial timetable. LCP's unique, patented delivery technology, MeltDose®, can improve absorption and bioavailability ‐ at low‐scale up costs ‐ not only for a broad spectrum of drugs already on the market but also for new chemical entities. LCP has a lipid lowering product, Fenoglide®, currently on the U.S. market and a diversified near and medium term pipeline with three clinical stage product candidates and a number of projects in preclinical development. LCP is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: LCP. For further information, please visit www.lcpharma.com


Attachments

04052011 LifeCycle Pharma Host Q1 2011 Interim Report Conference Call.pdf